Ling Peng
Guangzhou University of Chinese Medicine
ORCID: 0000-0002-1359-4982Also affiliated with Union Hospital, Central South University, East China Jiaotong University, University of Electronic Science and Technology of China, Guangxi University, Hunan Normal University, Wuhan University of Technology, Hainan University, Sichuan University, Hebei University of Science and Technology, Beijing VDJBio (China), Beijing Microelectronics Technology Institute, China General Nuclear Power Corporation (China), Sichuan Cancer Hospital, Wuhan Ship Development & Design Institute, Zhejiang Provincial People's Hospital, Xiangya Hospital Central South University, Hangzhou Medical College, Huazhong University of Science and Technology, China Southern Power Grid (China)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 1 paper. Top paper: “A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib”.
Kui Xiao, Silvia Ottaviani, Justin Stebbing, Ying-Jie Wang, Ling Peng